Status:
UNKNOWN
Immunophenotyping and Xist Gene in AML
Lead Sponsor:
Assiut University
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
Brief Summary
Acute myeloid leukemia (AML) is a heterogeneous disorder characterized by clonal expansion of myeloid progenitors (blasts) in the bone marrow and peripheral blood.Several studies have reported correla...
Detailed Description
Acute myeloid leukemia (AML) is a heterogeneous disorder characterized by clonal expansion of myeloid progenitors (blasts) in the bone marrow and peripheral blood. with high mortality and variable pro...
Eligibility Criteria
Inclusion
- AML patients, who fulfill the WHO 2016 criteria
Exclusion
- patients with other hematological nepolasms (ALL,CLL, plasma cell myeloma)
Key Trial Info
Start Date :
October 2 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT04288739
Start Date
October 2 2020
End Date
December 31 2022
Last Update
July 9 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of medicine
Asyut, Egypt, 71515